It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We describe the design, kinetic properties, and structures of engineered subtilisin proteases that degrade the active form of RAS by cleaving a conserved sequence in switch 2. RAS is a signaling protein that, when mutated, drives a third of human cancers. To generate high specificity for the RAS target sequence, the active site was modified to be dependent on a cofactor (imidazole or nitrite) and protease sub-sites were engineered to create a linkage between substrate and cofactor binding. Selective proteolysis of active RAS arises from a 2-step process wherein sub-site interactions promote productive binding of the cofactor, enabling cleavage. Proteases engineered in this way specifically cleave active RAS in vitro, deplete the level of RAS in a bacterial reporter system, and also degrade RAS in human cell culture. Although these proteases target active RAS, the underlying design principles are fundamental and will be adaptable to many target proteins.
Chen et al. describe a rational design of subtilisin mutants that degrade active RAS by cleaving a conserved sequence in switch 2. They further modified the active site to be dependent on a cofactor to generate high target specificity. Proteases engineered to cleave this region degraded RAS in vitro and in cells with a promise of adaptability for other target proteins too.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Potomac Affinity Proteins, North Potomac, USA (GRID:grid.423246.5)
2 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5); Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.411024.2)
3 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5)
4 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.423246.5); University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
5 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.411024.2); National Institute of Standards and Technology and the University of Maryland, Rockville, USA (GRID:grid.94225.38) (ISNI:000000012158463X)
6 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.94225.38); University of Maryland, Department of Bioengineering, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177)
7 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); National Institute of Standards and Technology and the University of Maryland, Rockville, USA (GRID:grid.94225.38) (ISNI:000000012158463X)
8 Unified Culture Collection, United States Army Research Institute of Infectious Diseases, Fort Detrick, USA (GRID:grid.94225.38)
9 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); University of Maryland, Department of Bioengineering, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177); Institute for Bioengineering of Catalonia of the Barcelona Institute of Science and Technology & Institution of Catalonia for Research and Advanced Studies, Barcelona, Spain (GRID:grid.424736.0) (ISNI:0000 0004 0536 2369)
10 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.424736.0); Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); Center for Biomolecular Therapeutics, Rockville, USA (GRID:grid.411024.2); University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
11 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.411024.2); University of Maryland, Department of Chemistry and Biochemistry, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177)
12 Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.164295.d); University of Maryland, Department of Cell Biology and Molecular Genetics, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177)
13 Potomac Affinity Proteins, North Potomac, USA (GRID:grid.423246.5); Institute for Bioscience and Biotechnology Research, Rockville, USA (GRID:grid.423246.5)